Cagrilintide
Price range: ÂŁ44.99 through ÂŁ58.99
Cagrilintide
Metabolic — Amylin Analogue Cagrilintide
A long-acting amylin analogue under development by Novo Nordisk.
Amylin is a pancreatic peptide co-secreted with insulin that regulates appetite and gastric emptying.
Combined with semaglutide in the CagriSema formulation, Phase III trials have demonstrated up to 22.7% mean weight loss — approaching the efficacy of surgical interventions.
- Class: Long-acting amylin analogue
- Developer: Novo Nordisk
- Stage: Phase III (CagriSema combination)
Cagrilintide
Mechanism of Action
Cagrilintide binds amylin receptors (AMY1-3) in the hypothalamus and area postrema, reducing appetite through a complementary pathway to GLP-1 agonism — acting on calcitonin receptor complexes that mediate satiety and slow gastric emptying.
Complementary to GLP-1
Amylin and GLP-1 receptor systems act through partially distinct hypothalamic circuits. Dual activation with cagrilintide + semaglutide (CagriSema) produces additive weight loss beyond either agent alone — the rationale for combining them in Phase III trials.
REDEFINE Phase III
The REDEFINE-1 trial of once-weekly CagriSema (2.4 mg sema + 2.4 mg cagrilintide) demonstrated 22.7% mean weight reduction at 68 weeks, with over 40% of participants achieving ≥25% weight loss.
Research compound only — not licensed for human consumption or therapeutic use. Sold strictly for laboratory research purposes.
Vials (Peptides)
Pre-mixed Pens (Peptides)
Nasal Spray (Peptides)
Cream (Peptides)
Reviews
There are no reviews yet.